NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) - Reportlinker.com na-ekwupụta mwepụta nke akụkọ ahụ "Global Intravenous Therapy and Intravenous Access Market Size, Share and Industry Trends Analysis Report, Outlook and amụma nke onye ọrụ njedebe, ngwa, ụdị, mpaghara, 2022-2028" - https://www.reportlinker.com/p06283441/?utm_source=GNW Ụzọ kachasị ngwa ngwa iji tinye mmiri n'ime akụkụ ahụ dị iche iche bụ site na ọgwụgwọ IV. Ọrịa obi, ọrịa strok, na nsị na-eji ọgwụ a eme ihe. N'okwu a, a ga-agwọ onye ọrịa ahụ ọgwụ ozugbo enwere ike, si otú a na-enye ọgwụ ahụ n'ime intravenously, ọgwụ nje, ọgwụgwọ antifungal. A na-enye ọgwụ mgbochi ọbara n'ime intravenously.Intravenous therapy (IV) bụ usoro nke na-ebuga ọgwụ na mmiri mmiri n'ime ahụ site na vein. A na-enye ọgwụ ndị nwere vitamin na mineral site na ntapu nke eriri afọ ma ọ bụ ntụtụ n'ime eriri afọ, na-ekwe ka ọgwụgwọ na-asọba ngwa ngwa site n'ọbara. Nke a bụ usoro nchịkwa nke IV bụ mgbe onye ọrịa ahụ na-eji ihe dị n'akụkụ a na-akpọ vein. a ọgwụ ma ọ bụ a nutritional deficiency.IV ọgwụgwọ bụ ahụkarị ụzọ na-enye mmiri mmiri, ọgwụ, ọgwụ, kemoterapi, na mmịnye ọbara nye ndị ọrịa dehydrated.N'oge IV ochichi, dị iche iche IV ngwá dị ka IV catheters, infusion nfuli, immobilization ngwaọrụ, na nchịkwa nchịkwa na-eji.IV ọgwụgwọ nlekọta ngwa ngwa, dị mfe ịgbaso, na ọ dịghị enwe eriri afọ mmetụta na-adịghị ala ala na-adịghị emetụta usoro ahụ ji alụso ọrịa ọgụ ka ọ na-akwalite usoro ọgwụgwọ na-adịghị ala ala. mgbapụta nke na-achịkwa ọnụọgụ kemịkalụ a ga-enye ahụ ma nwee ike ileba anya ngwa ngwa. A na-atụ anya na ahịa ọgwụgwọ intravenous zuru ụwa ọnụ na ngwaọrụ ịnweta intravenous ga-abawanye n'oge amụma. Ọganihu nke ọrịa shuga, ịrị elu nke ihe mberede okporo ụzọ, na mmụba nke usoro ịwa ahụ na-atụ anya ịkwalite ụlọ ọrụ ahụ n'ihu. A na-ebutekwa ụlọ ọrụ ahụ site na-eto eto na-achọ ọgwụ na-enweghị mkpa, dị ka COVID-1 nke na-ebufe ọgwụ dị otú ahụ. COVID-19 nwere mmetụta dị mma n'ozuzu ya na ahịa ọgwụgwọ IV. N'ime ndị ọrịa nwere nnukwu ọrịa iku ume iku ume metụtara COVID-19, a na-enye ọgwụgwọ IV (ARDS).Dịka ọmụmaatụ, iji ọgwụ mgbochi globulin intravenous maka ọgwụgwọ COVID-19 ARDS dị ka ihe na-adọrọ adọrọ maka ọgwụgwọ COVID-19 metụtara ARDS siri ike, n'ihi na ebipụtara ya na The Lancet. iji modulate multiple immunocompartments simultaneously.Ya mere, na mmụba nke ọnụ ọgụgụ nke ndị ọrịa na COVID-19 metụtara ARDS, ọchịchọ nke IV therapy na intravenous ngwaahịa ohere na-abawanye.Azụmahịa Uto Ihe Na-abawanye Operations na Growing Geriatric Population Ọnụ ọgụgụ nke ọrịa dị iche iche na-adịghị ala ala nke na-achọ ọgwụgwọ akwara vaskụla abawanyela n'oge gara aga, ọrịa cancer dị iche iche dị ka ọrịa obi na-ada mbà n'oge gara aga. dị ka ọbara mgbali elu, ọrịa shuga, oke ibu na ịda mbà n'obi, chọrọ nlekọta kpụ ọkụ n'ọnụ n'oge ọnụnọ ụlọ ọgwụ.N'ime afọ ole na ole sochirinụ, ibuwanye ibu nke ọrịa na-adịghị ala ala dị ka ọrịa obi, ọrịa cancer, ọrịa strok, na ọrịa shuga, tinyere ọnụ ọgụgụ ndị agadi, ga-eme ka ọ dịkwuo mkpa maka ọgwụgwọ intravenous. Technology Advances Intravenous catheters (peripheral and central), nke na-enye aka na akụrụngwa nchekwa, nke na-etinye aka na akụrụngwa nchekwa, nke na-etinye aka na akụrụngwa nchekwa. High-quality intravenous therapy (IVT) practice. Dị ka nkà na ụzụ ahụike bụ ịdọ aka ná ntị dị mgbagwoju anya, na ntụgharị uche na mkparịta ụka kwa ụbọchị site n'aka ndị ọkachamara ahụike na-etinye aka na nlekọta ndị ọrịa na ngalaba nlekọta ahụ ike, ngalaba nlekọta ahụ emeela mgbanwe dị ịrịba ama n'ihi ntinye nke teknụzụ ọhụrụ, na nfuli infusion nke ịkpụ bụ otu n'ime ihe ndị na-emepụta ihe iji nyere aka nweta ihe nchebe na nke dị elu na-achọ ọgwụgwọ na-arụ ọrụ nke PumpT Constravenous. Usoro iwu siri ike na nchegbu banyere nsogbu. A na-ebugharị usoro ikike maka ọrụ ọhụrụ na mmepụta mgbapụta na nchikota. Ọzọkwa, na-echeta ngwaahịa na-arị elu n'ihi nrụpụta nrụpụta ga-ebelata nnabata nke usoro ọgwụgwọ ndị a. Dị ka ihe atụ, Fresenius Kabi chetara Vigilant Agilia Drug Depot na Volumat MC Agilia Infusion Pump na August 2010 na-emepe emepe n'ihi na ọ na-eme ka ọ dị ntakịrị ihe na-emepe emepe. (KVO) na ndị ọzọ software chinchi.A isi ihe mgbochi na uto nke ụlọ ọrụ bụ nsogbu metụtara ojiji nke IV ụzọ na IV infusion ngwaahịa.End User Outlook Dabere na njedebe onye ọrụ, ahịa na-segmented n'ime ụlọ ọgwụ, ambulatory ịwa ahụ centre, na clinics.The ụlọ ọgwụ ngalaba ga-eweghara kasị ukwuu revenue òkè na intravenous (IV) ahịa na-abawanye na venous1 ahịa na ọnụ ọgụgụ nke 20 n'ihi na nke a na-enweta venous. ịwa ahụ a rụrụ ma e jiri ya tụnyere ụlọ ọrụ ịwa ahụ ambulatory na ụlọ ọgwụ. Tụkwasị na nke ahụ, a na-ekwu na uto nke akụkụ ahụ bụ mmụba nke ọgwụgwọ intravenous n'ụlọ ọgwụ, nke gụnyere ọgwụ nje ọgwụ nje, ọgwụ maka ndị ọrịa comatose, ọgwụ ndị a na-apụghị iji ọnụ, redio na-eme ihe, ọgwụ mgbochi ọrịa cancer, hemodialysis, na-emeghachi usoro ọgwụgwọ ọbara na-eto eto n'ihi na ngwaọrụ IV, na mmịnye ọbara. Ọganihu teknụzụ na itinye ego n'ụlọ ọgwụ.Ndabere nke ngwa, ahịa ahụ kewara n'ime nchịkwa ọgwụ, ngwaahịa ndị sitere na ọbara, ihe oriri na-edozi ahụ na arịa mgbasawanye. Na 2021, ngalaba Expander nke Mpịakọta ga-enweta oke ego ha nwetara na ọgwụgwọ intravenous (IV) yana ohere ịnweta venous. agbanyeghị, ọnụ ọgụgụ mmiri mmiri nwere ike ịba uru maka obere mmiri mmiri maka ndị na-eme egwuregwu dị elu nwere akụkọ ihe mere eme nke mgbaàmà siri ike n'okpuru nlekọta dị mma.Ụfọdụ ndị na-eme egwuregwu nwere ike irite uru site na iji ihe na-agbasawanye. A na-amachibidoro mmiri na-agbapụta n'ime mmiri na plasma na asọmpi WADA na-achịkwa. Maka ọnụ ọgụgụ ka ukwuu nke ndị na-eme egwuregwu, usoro ọgwụgwọ IV na-emekarị abụghị nhọrọ kachasị mma. Ụdị Outlook Dabere na ụdị, a na-ekewa ahịa ahụ n'ime intravenous needles, infusions captheters, infusions na ndị ọzọ. N'afọ 2021, akụkụ catheter intravenous ga-enweta oke ego ha nwetara na ọgwụgwọ intravenous (IV) na ahịa ohere venous. Nke a bụ n'ihi mmụba nke IV catheters n'oge usoro ịwa ahụ maka ọgwụgwọ IV yana n'oge a na-ebufe ọbara, ọgwụ na nri ndị ọzọ n'akụkụ dị iche iche nke ahụ. A na-ebubata ọgwụ, mmiri mmiri, ma ọ bụ ọgwụgwọ ndị ọzọ ozugbo n'ime ọbara. A na-ebutekarị ha n'ime akwara na ogwe aka, ọ bụ ezie na a pụkwara itinye ha n'olu, obi, ma ọ bụ groin. 2021, North America bụ mpaghara na-ebute ụzọ na ọgwụgwọ intravenous (IV) na ahịa ohere venous site na iwere oke ego ahịa ahịa kachasị elu. Enwere ike ịsị na uto nke ahịa mpaghara na mmụba nke ọnụ ọgụgụ ndị ọrịa, ịrị elu nke ihe ọghọm okporo ụzọ, nnukwu uto n'ọnọdụ trauma, yana ịba ụba itinye ego gọọmentị etiti n'ịzụlite ụlọ ọrụ ahụike ka mma na ụlọ ọrụ nyocha R&D na-ekpuchi profaịlụ ahịa ahịa. N'ime akụkọ a gụnyere B. Braun Melsungen AG, Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGaA, Cardinal Health, Inc., Pfizer, Inc., Teleflex, Inc., Baxter International, Inc., Smiths Group PLC na AngioDynamics, Inc. Deploy Strategies in the Intravenous (IV) The Intravenous Market2 Intravenous (IV). bịanyere aka n'akwụkwọ nkwado iji nweta Fresenius Kabi, a zuru ụwa ọnụ ike ụlọ ọrụ.The nnweta, e mere ka iwekota Ivenix' enwekwukwa infusion usoro n'ime Fresenius Kabi si Pọtụfoliyo nke igba intravenous infusion na infusion ọgwụgwọ ngwaahịa, ga-eme ka a sara mbara mix nke ngwaahịa na US hospitals.December 2021: Baxter ụdị mmekọrịta na US abụọ nkà na ụzụ na-eweta a Hillrom. Mee 2021: Smiths Medical form mmekorita ya na ụlọ ọrụ teknụzụ ahụike Ivenix. Site na mmekorita a, ụlọ ọrụ abụọ ahụ bu n'obi ịnye ọtụtụ ngwọta nchịkwa infusion. Na mgbakwunye, Smiths Medical ga-enye ntinye atụmatụ atụmatụ na mmekorita ogologo oge e mere iji gbanwee njikwa ngwakọta na ịkwalite ahụike nke onye ọrịa April2. weputara mmemme ohuru, Peripheral Advantage, iji meziwanye ahụmịhe nke ndị ọrịa na ọgwụgwọ intravenous mpụta. Mmemme ahụ na-ejikọta ntuziaka ụlọ ọgwụ, data sitere n'uche, na ngwaọrụ ndị dị mma iji mee ka ndị nọọsụ nwee ike nweta ihe ịga nke ọma nke mbụ ma nyere aka zere mgbagwoju anya metụtara ọgwụgwọ IV .July 2019: Baxter na-enweta nnabata US Food and Drug Administration (FDA) maka nkwado insulin ozugbo. infusion intravenous n'ụlọ ọgwụ na ntọala nlekọta ahụike ndị ọzọ ma nwee ogologo ndụ zuru oke nke ụbọchị 30 ma ọ bụ ọnwa 24 n'ime ụlọ okpomọkụ ma ọ bụrụ na etinyere ya na ngwa nju oyi na nkwakọ ngwaahịa mbụ iji hụ na nchebe pụọ na ìhè. Pumps • Hypodermic Needles • Ndị ọzọ site na Geography • North America o USo Canadao Mexico Rest of North America • Europe Germany o UKo France Russia Spain Italy o Rest of Europe • Asia Pacific China o Japan India Korea Singapore Malaysia o fọdụrụ Asia Pacific • LAMEAo Brazil Argentina UAE Saudi Arabia South Africa Nigeria LAMEA Rest Company Profaịlụ • B. Braun Melsungen Co. KGaA• Cardinal Health, Inc.• Pfizer, Inc.• Teleflex, Inc.• Baxter International, Inc.• Smiths Group PLC• AngioDynamics, Inc. Onyinye pụrụ iche • mkpuchi na-agwụ agwụ • Tebụl Ahịa & Data Kachasị ukwuu • Ụdị ndebanye aha dabeere na ndenye aha dị • Ọnụ ahịa kacha mma akwadoro • 1 Nleba anya n'efu n'efu site na agụpụta n'efu site n'aka 0. https://www .reportlinker.com/p06283441/?utm_source=GNWAbout ReportlinkerReportLinker bụ ngwọta nyocha ahịa na-emeri.Reportlinker na-achọta ma hazie data ụlọ ọrụ kachasị ọhụrụ ka ị nwee ike nweta nyocha ahịa niile ịchọrọ ozugbo n'otu ebe.
Oge nzipu: Jun-28-2022